Glad that we're thinking alike on that point. Can you imagine if (heaven forbid) the ultimate pk/pd individual participant data is released and there's no significant dose-dependent correlation with test scores?
They've just finished a legal challenge from a disgruntled investor about 8 months ago. Maybe they're cognizant of their public representations at this point?
He said plainly in the presentation and in the 2017 catalysts slide that those pk/pd data will be released next.
And he's standing there at an INVESTOR conference making very clear statements & assertions about this important efficacy point, seems to me.
Dr M has likely pored over the 15/18 month data a thousand times by now (assumably with his SAB members and legal team); probably has much of the data memorized at this point frankly.
I find it a stretch for someone (other than those with intimate knowledge of the trial data) to tell me with any certainty that "the dose dependency is still not strong".
News 
Market Data 
Discover 
